CDNA Stock Recent News
CDNA LATEST HEADLINES
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its kind, published in The Journal of Heart and Lung Transplantation.
CareDx, Inc. (NASDAQ:CDNA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director of Investor Relations John Hanna - President & Chief Executive Officer Abhishek Jain - Chief Financial Officer Alex Johnson - President-Patient & Testing Services Conference Call Participants Bill Bonello - Craig-Hallum Capital Group Prashant Kota - Goldman Sachs Mason Carrico - Stephens Operator Good day, everyone, and welcome to today's CareDx, Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.